Tarsus Pharmaceuticals Inc
NASDAQ:TARS

Watchlist Manager
Tarsus Pharmaceuticals Inc Logo
Tarsus Pharmaceuticals Inc
NASDAQ:TARS
Watchlist
Price: 78.28 USD -2.73% Market Closed
Market Cap: 3.3B USD

EV/EBITDA
Enterprise Value to EBITDA

-35
Current
-6.2
Median
13
Industry
Lower than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-35
=
Enterprise Value
3B USD
/
EBITDA
-85.6m USD
All Countries
Close
EBITDA Growth EV/EBITDA to Growth
US
Tarsus Pharmaceuticals Inc
NASDAQ:TARS
Average EV/EBITDA: 438.8
Negative Multiple: -35
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36.3
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.4
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.4
4%
2.9
UK
AstraZeneca PLC
LSE:AZN
108.7
10%
10.9
CH
Novartis AG
SIX:NOVN
11.5
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.2
6%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
9.1
2%
4.6
IE
E
Endo International PLC
LSE:0Y5F
331.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
1%
7.5

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
-46.4
2-Years Forward
EV/EBITDA
32.4
3-Years Forward
EV/EBITDA
10.6